https://www.selleckchem.com/products/ptc-028.html
87.8% and 82.2% susceptibility to imipenem-relebactam was observed for 188 carbapenem-nonsusceptible E. coli and 472 carbapenem-nonsusceptible K. pneumoniae, respectively. However, poor activities of imipenem-relebactam was observed against 23 metallo-carbapenemase producers tested in this study. In the invivo C. elegans model, imipenem-relebactam significantly rescued nematodes from the infection of a bla -producing K. pneumoniae isolate. Our study supports that imipenem-relebactam is a potential therapy against carbapenem-nonsusceptib
Like
Comment
Share
